Synonym
Glamidolo; Reversil; Dapiprazole; Dapiprazol;
IUPAC/Chemical Name
3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
InChi Key
RFWZESUMWJKKRN-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
SMILES Code
CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
325.45
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ramesh T, Rao PN, Rao RN. Development of LC-MS/MS method for the determination of dapiprazole on dried blood spots and urine: application to pharmacokinetics. Biomed Chromatogr. 2014 May;28(5):615-20. PubMed PMID: 24847516.
2: Ramesh T, Rao PN. Development and validation of a stability-indicating RP-HPLC assay method and stress degradation studies on dapiprazole. J Chromatogr Sci. 2013 Oct;51(9):856-60. doi: 10.1093/chromsci/bms184. Epub 2012 Nov 20. PubMed PMID: 23169931.
3: Canovetti A, Nardi M, Figus M, Fogagnolo P, Benelli U. Aceclidine, brimonidine tartrate, and dapiprazole: comparison of miotic effect and tolerability under different lighting conditions. J Cataract Refract Surg. 2009 Jan;35(1):42-6. doi: 10.1016/j.jcrs.2008.09.009. PubMed PMID: 19101423.
4: Marx-Gross S, Krummenauer F, Dick HB, Pfeiffer N. Brimonidine versus dapiprazole: Influence on pupil size at various illumination levels. J Cataract Refract Surg. 2005 Jul;31(7):1372-6. PubMed PMID: 16105609.
5: Giakoumaki SG, Hourdaki E, Grinakis V, Theou K, Bitsios P. Effects of peripheral sympathetic blockade with dapiprazole on the fear-inhibited light reflex. J Psychopharmacol. 2005 Mar;19(2):139-48. PubMed PMID: 15728435.
6: Leccisotti A. Dapiprazole for night halos caused by angle-supported phakic intraocular lenses. J Refract Surg. 2004 Sep-Oct;20(5):489. PubMed PMID: 15523962.
7: Schmidbauer JM, Georg T, Möller MR, Ruprecht KW. [Driving ability after reversal of phenylephrine 10% induced mydriasis by dapiprazole 0.5%; a prospective study on 65 eyes]. Klin Monbl Augenheilkd. 2000 Dec;217(6):340-4. German. PubMed PMID: 11210707.
8: Schimidbauer JM, Höh H, Franke G, Petsch E, Siegmund W. [Clinical use of mydriasis with 10% phenylephrine and its antagonism by 0.5% dapiprazole]. Ophthalmologe. 1999 Mar;96(3):182-6. German. PubMed PMID: 10234966.
9: Anicho UM, Cooper J, Feldman J, Jaanus SD, Dignam K. The clinical efficacy of paremyd with and without dapiprazole in subjects with light and dark brown irides. Optom Vis Sci. 1999 Feb;76(2):94-101. PubMed PMID: 10082055.
10: Eltze M. Affinity of the miotic drug, dapiprazole, at alpha 1-adrenoceptor subtypes A, B and D. J Pharm Pharmacol. 1997 Nov;49(11):1091-5. PubMed PMID: 9401944.
